Clinical Trial Assessing the Efficacy and Safety of Hépar® in Chronic Constipation

NCT ID: NCT03348007

Last Updated: 2017-11-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 262 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-30
• Study Completion Date: 2016-07-22

Brief Summary

The study objectives are to evaluate the efficacy and safety of a 2-week daily intake of 1L Hépar® natural mineral water rich in magnesium sulphate compared to a control natural mineral water in the treatment of the constipation symptoms in women outpatients.

Detailed Description

Healthy patients meeting all of the following criteria were included in the study: i) female outpatient aged 18 to 60, ii) with a diagnosis of functional constipation according to the Rome III criteria for 3 months or more, iii) without any laxative drug for 3 days prior to inclusion, iv) having easy access to toilet, v) regularly eating vegetables and fruits, vi) having physical activity, reasonable walking periods or exercise 2 or 3 times a week and vii) drinking 1.5±0.5L of water /day. Patients who presented any of the following criteria were excluded from the study: i) known unsatisfaction to Hépar, ii) concomitant treatment or disease (current or past) likely to interfere with evaluation of the study parameters and iii) documented pregnancy. The study was conducted by 28 city-based general practitioners located throughout France.

After a screening visit, patients followed a washout during 7 to 9 days before inclusion. Patients had to stop any drug treatment liable to interfere with transit and drink 1.5 litres per day of a low-mineral spring water (Nestlé Purelife, Nestlé Waters, France). At the inclusion visit, patients were randomized to the control or Hépar group according to the chronological order of inclusion and to a predetermined randomization list in balanced blocks of 4 treatment units (SAS® software). The randomization list was prepared in advance by the statistician from the society in charge of the logistic of bottles, and secured in an electronic file with restricted access. Two sets of sealed envelopes kept by the investigator and the study manager in a secure and locked place were generated to contain the patient's randomization number and allocated group. The investigator could break the blinding in case of absolute emergency and in accordance with the sponsor. The follow-up visit was performed 15 to 17 days following inclusion.

Patients had to drink 1.5L per day from day 1 to day 14. Depending of the randomization, they drank either 1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).

During the screening visit (V0), the physician collected sociodemographics, previous medical history and history of the constipation episode (Rome III criteria), onset of symptoms, abdominal pain on a 100 mm VAS, dietary habits, physical activities and previous and current treatments. The patient was provided with a self-evaluation e-diary to collect: i) the number and type of stools (Bristol Scale); ii) abdominal pain, iii) physical activity and iv) drug, water, beverage and food consumption during washout.

At inclusion (V1), the physician collected: i) the weekly number and type of stools, ii) Rome III criteria, iii) AEs, iv) ability to complete the e-diary, v) compliance to the washout treatment (count of unused bottles), and vi) use of rescue medication over the past week.

During the final visit (V2), the physician collected: i) the weekly number and type of stools, ii) Rome III criteria, iii) AEs, iv) compliance to the treatment (count of unused bottles) and v) use of rescue medication over the past two weeks.

For the washout and the treatment periods, the type of stools was assessed directly by the patient on the e-diary and secondarily by an independent expert, based on the photographs the patient had to make of each of their stools.

Conditions

Constipation - Functional

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

HEPAR

1L of Hépar + 0.5L of low-mineral water (Hépar group).

Group Type: EXPERIMENTAL

Taking two kinds of mineral water

Intervention Type: OTHER

1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).

VITTEL Bonne Source

1.5L of low-mineral water (Vittel Bonne Source, control group)

Group Type: ACTIVE_COMPARATOR

Taking two kinds of mineral water

Intervention Type: OTHER

1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).

Interventions

Taking two kinds of mineral water

1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Women, aged 18 to 60.
• Outpatients.
• Diagnosis of constipation according to the Rome III criteria Symptoms ≥3 months Onset ≥6 months prior to diagnosis

a. Presence of ≥2 of the following symptoms for at least 25% of defecations: straining, lumpy or hard stools, sensation of incomplete evacuation, sensation of ano-rectal obstruction/blockage, manual maneuvers to facilitate defecation (e.g., digital evacuation, support of the pelvic floor), <3 defecations/week and b. Loose stool rarely present without use of laxative and c. Insufficient criteria for Inflammatory Bowel Syndrome with constipation (IBS-C)

• No laxative drug for ≥ 3 days preceding the inclusion.
• Easy access to toilet at work or elsewhere.
• Regularly consumption of vegetables and fruits.
• Physical activity 2 or 3 times a week.
• Consumption of 1.0 L to 1.5 L of water per day.
• Signed informed consent.
• Ability to follow the study instructions.
• Health insurance coverage.

Exclusion Criteria

• Current pregnancy.
• Severe or acute disease likely to interfere with the results of the study or to be life-threatening.
• History of digestive disease, digestive malformation.
• Metabolic disease.
• Dysfunction of phospho-calcium metabolism.
• History of renal disease (renal insufficiency etc.) or cardio-vascular disease (cardiac insufficiency...), respiratory disease, neural disease.
• Subject on local or general treatment (prescribed drugs, food supplements etc.) likely to interfere with evaluation of the study parameters, including hydration status and transit.
• Subject who refuses to sign the declaration of informed consent.
• Subject not available for the entire duration of the study.
• Subject having a bad acceptance to Hépar® water.
• Subject being currently treated with drugs that can interact on digestive motility: paraffin, mucilages, pro or prebiotics, lactulose, lactitol, PEG.
• Subject has participated in a clinical trial within 3 months prior to baseline visit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Quanta Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Baudouin TCHAKONTE, MD

Role: PRINCIPAL_INVESTIGATOR

44340 Bouguenais France

Locations

Quanta Medical

Rueil-Malmaison, , France

Countries

France

Other Identifiers

2014-A00948-39

Identifier Type: -

Identifier Source: org_study_id